Novartis AG (NYSE:NVS) shares were down over 2% in regular trading Thursday as the company rolled forward its mid-term financial guidance to cover 2026 through 2031, projecting net sales to grow at a 5% constant currency compound annual growth rate.
The pharmaceutical company also expects its core operating income margin to return to at least 40% by 2029.
Higher Peak Sales Targets for Core Brands
Management boosted peak sales guidance for three major commercial medicines, reinforcing confidence in its multi-year trajectory.
Novartis raised its peak sales forecast for Kesimpta from $6 billion to $8 billion, while lifting projections for both Scemblix and Leqvio from $4 billion to $5 billion each.
These increases follow a recent peak sales upgrade for Rhapsido, or remibrutinib, to $8 billion across chronic spontaneous urticaria, chronic inducible urticaria and relapsing multiple sclerosis.
Novartis also sees multi-billion-dollar potential for Rhapsido across additional indications.
Overall, the company says it now has nine de-risked, in-market assets with peak sales potential between $3 billion and $10 billion.
Alongside Kesimpta, Scemblix, Leqvio and Rhapsido, this group includes Kisqali, Cosentyx, Pluvicto, Fabhalta and the Zolgensma Group, comprising Zolgensma and Itvisma.
Deep Clinical Pipeline Supports Long-Term Growth
Beyond its marketed portfolio, Novartis anticipates 35 or more potentially submission-enabling clinical readouts through 2031.
The company’s pipeline includes 30 or more potential high-value assets across four core therapeutic areas and three advanced technology platforms, including 10 late-stage assets with multi-billion-dollar peak sales guidance.
The pipeline includes 20 or more assets in registration, Phase 3 or Phase 2, with 10 or more in or entering Phase 1 studies.
Novartis expects these programs to support sustained mid-single-digit sales growth over the long term.
NVS Price Action: Novartis AG shares were down 2.33% at $151.60 at last check Thursday, according to Benzinga Pro data.
Photo: Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.





